-98.3%
DFNS vs MRNA
+511.3%
-609.6%
-99.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.6% | -2.2% | +2.8% | +0.7% |
| 7D | -16.0% | +5.5% | -21.5% | -16.3% |
| 30D | -77.7% | +158.7% | -236.4% | -80.1% |
| 3M | -77.2% | +182.1% | -259.3% | -78.0% |
| 6M | -95.2% | +151.8% | -247.0% | -95.3% |
| YTD | -98.0% | +393.6% | -491.5% | -98.1% |
| 1Y | -98.3% | +499.5% | -597.7% | -98.5% |
| All | -98.3% | +511.3% | -609.6% | -98.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling